TGF-β inhibitor LY2157299 (galunisertib) in combination with standard chemotherapy and inhibition of signaling to pSmad and EMT and suppression of tumor growth in gastric cancer.

被引：6
|
作者：
Miyoshi, Sawako
Kudo, Masahisa
Shitara, Kohei
Yamauchi, Mayumi
Doi, Toshihiko
Matsumura, Yasuhiro
机构：
[1] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[2] Natl Canc Ctr Hosp East, Res Ctr Innovat Oncol, Div Dev Therapeut, Kashiwa, Chiba, Japan
[3] Natl Canc Ctr East, Chiba, Japan
[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.50
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
50
引用
收藏
页数：1
相关论文
共 6 条
  • [1] Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
    Armin Maier
    Anne-Lise Peille
    Vincent Vuaroqueaux
    Michael Lahn
    Cellular Oncology, 2015, 38 : 131 - 144
  • [2] Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
    Maier, Armin
    Peille, Anne-Lise
    Vuaroqueaux, Vincent
    Lahn, Michael
    CELLULAR ONCOLOGY, 2015, 38 (02) : 131 - 144
  • [3] LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer
    Zhang, Qing
    Hou, Xiaonan
    Evans, Bradley J.
    VanBlaricom, Jamison L.
    Weroha, Saravut J.
    Cliby, William A.
    CANCERS, 2018, 10 (08)
  • [4] Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II
    Dituri, Francesco
    Mazzocca, Antonio
    Juan Peidro, Fernando
    Papappicco, Patrizia
    Fabregat, Isabel
    De Santis, Flavia
    Paradiso, Angelo
    Sabba, Carlo
    Giannelli, Gianluigi
    PLOS ONE, 2013, 8 (06):
  • [5] Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in patients with advanced cancer.
    Kozloff, Mark
    Carbonero, Rocio
    Nadal, Tamara
    Gueorguieva, Ivelina
    Cleverly, Ann
    Desaiah, Durisala
    Lahn, Michael M. F.
    Pillay, Sada
    Blunt, Al
    Tabernero, Josep
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II (vol 8, e67109, 2013)
    Dituri, F.
    Mazzocca, A.
    Peidro, F. J.
    Papappicco, P.
    Fabregat, I
    PLOS ONE, 2014, 9 (06):
1